
The CardioMEMS European Monitoring Study for Heart Failure (MEMS‐HF) investigated the safety and efficacy of pulmonary‐artery‐pressure (PAP)‐guided remote patient management (RPM) in New York Heart Association (NYHA) Class III outpatients with at least one hospitalization for heart failure (HFH) during the previous 12 months. Outpatients with NYHA Class III symptoms with ≥ one HFH during one-year pre‐implant benefitted significantly from PAP‐guided RPM during post‐implant follow‐up, irrespective of presence or subtype of PH at baseline.
Like
Save
Share